Should we substantially limit the reporting of incidental findings?

Sharon E. Plon, MD, PhD, FACMG
Baylor College of Medicine
@splon
My initial hypotheses & biases

• I’m quite troubled by the potential difficulty in effectively classifying variants on the ACMG59 for reporting incidental findings (IF).
• Some have clear loss of function alleles and phenotypes but missense alleles are very difficult to classify.
• ACMG classification rules may improve our ability to do this but still not easy.
• Reclassification from pathogenic to benign is clinically troubling, particularly in the incidental setting (do no harm).
• Some genes maybe too new to know the spectrum well.
• Some genes have very broad phenotypes so what exactly is patient at risk for?
• My starting bias was reporting of IF in cancer genes is easier (but not simple) compared with cardiovascular genes.
Genetic Misdiagnoses and the Potential for Health Disparities

Arjun K. Manrai, Ph.D., Birgit H. Funke, Ph.D., Heidi L. Rehm, Ph.D., Morten S. Olesen, Ph.D., Bradley A. Maron, M.D., Peter Szolovits, Ph.D., David M. Margulies, M.D., Joseph Loscalzo, M.D., Ph.D., and Isaac S. Kohane, M.D., Ph.D.
Examples of reclassification from Pathogenic to Benign (or LB)

1. 2004 - 29 yr old postdoc with retinal hemangioma. VHL done at ”top” lab – c.340+5G>C clearly stated to be pathogenic with mRNA defect described on the report.
   • 12 years later in for follow-up at another center. No other features of VHL developed (although only intermittent screening)
   • Now BENIGN in ClinVar – 4.5% frequency in Han Chinese (patient is Chinese).

2. **DSP** c.88G>A (p.V30M) IF in child in 2013
   • Now reclassified based on frequency in ExAC data as BENIGN

3. LDLR missense variant reported as pathogenic (c.58G>A (p.G20R) in both symptomatic patient and IF
   • Now classified as VUS based on ACMG rules although still very rare and not completely clear to me why it was reclassified?
Method

- Took the ACMG59 list
  - Focused on cancer (n=24) and cardiovascular (n=28) genes
- Reviewed each one in OMIM and other references and assessed:
  - Date gene-variant/disease first published (before or after 2000)
  - Looked at majority of disease variants (truncating, mix of LOF/missense, or primarily missense)
  - Looked at other features – how many reported cases, variety of variants
  - Looked at Mendelian segregation and phenotypic heterogeneity
  - Presence of an Expert Panel in ClinVar
Overview of the ACMG59 Genes

ACMG 59 Gene Characteristics

- Number
- Before 2000
- After 2000
- ClinVar Expert Panel
- Loss of Function
- LOF/Missense
- Missense

Cancer
- Number: 25
- Before 2000: 20
- After 2000: 5
- ClinVar Expert Panel: 10
- Loss of Function: 15
- LOF/Missense: 5
- Missense: 0

Cardiovascular
- Number: 30
- Before 2000: 25
- After 2000: 5
- ClinVar Expert Panel: 15
- Loss of Function: 10
- LOF/Missense: 10
- Missense: 0
However, even newer genes aren’t that new

More Recently Described IF Genes

- SDH8
- MYH7
- RYR2
- BMPR1A
- MUTH
- DSP
- PK2
- MYH11
- TGFR1
- TGFR2
- DSC2
- DSG2
- ACTA2
- TMEM43
- SDHAF2
- SMAD3
Other complications for interpretation/implementation as IF

• Although most conditions are autosomal dominant there are other Mendelian conditions:
  • X-linked – Fabry (do you report both males & females)?
  • Autosomal recessive – MUTYH (do you report single carriers)?
  • Many genes have both dominant and more severe recessive phenotypes – complicates counseling
  • Digenic conditions – again do you report a single allele?

• A few conditions have only a few known disease alleles/founders.
  • Perhaps only report these well documented ones, e.g. TMEM43, SDHAF2
Extraordinarily wide range of alleles and quality of information

• Some genes, e.g. BRCA1 have thousands of documented alleles (LOF and missense) with Expert Panel interpretation

• Some genes have a few well documented alleles and then a range of other rare ones (MUTYH)

• Some extremely rare conditions with little allele information (CACNA1S, ACTC1)

• A number of other “messy genetics”
  • PMS2 – numerous pseudogenes may report “wrong” allele
  • Genetic modifiers - do labs have to look for those if they substantially impact the at-risk phenotype
My conclusion

• I’m not clear we are doing overall good reporting IF’s
• Reporting variants in many of these genes is difficult despite decades of knowledge!
• Should consider substantial simplification of the current IF recommendations if we continue reporting them
  • Consider dropping some of the very rare or recessive conditions unless quite common
  • Develop specific IF rules/technical guidance for each gene on the ACMG59
    • Strict LOF definition
    • From single to panel of missense to report (perhaps update yearly)
    • Any other gene specific complications (common modifier)
• Develop a one sheet IF description including any lab guidance, clinical aspects, next steps for each gene on list:
  • Similar to the newborn screening fact sheets